EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug Development

Denis Horgan iD, Zorana Maravic iD, Ken Mastris, Hadi Mohamad Abu Rasheed iD, Carolina Reduzzi iD, Adda Bounedjar iD, Hesham Elghazaly, Alejandro Mohar, Roberto Pestana iD, Jonathan A Lal iD, Umberto Malapelle iD, Ramin Asgary und 1 weitere

JCO Global Oncology · 2026

DOI: 10.1200/go-25-00285 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JCO Global Oncology, 2026. Verfasst von Denis Horgan und 12 weiteren Autor:innen. Beteiligte Einrichtung: European Alliance for Personalised Medicine, Brussels, Belgium. Hauptthemen laut MEDLINE: Drug Development, Neoplasms, Clinical Trials as Topic, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Global oncology trials face increasing scrutiny over regional enrollment imbalances, as regulatory agencies such as the US Food and Drug Administration, European Medicines Agency, and Pharmaceuticals and Medical Devices Agency demand data reflective of population diversity. This push is grounded in evidence that genetic polymorphisms (eg, UGT1A1* 28, CYP2D6 ), human leukocyte antigen–related toxicities, and biomarker prevalence (eg, epidermal growth factor receptor mutations in approximately 15% of Western v approximately 50% of Asian patients with lung cancer) can significantly influence treatment outcomes. METHODS We reviewed scientific literature, regulatory case studies, and methodological innovations addressing regional heterogeneity in oncology trials. Particular focus was given to statistical tools such as adaptive randomization for real-time enrollment balancing, Bayesian hierarchical models for data borrowing across regions, and Multi-Regional Clinical Trial designs for structured consistency assessments. Control arm variability because of regional differences in standard of care and drug access was also examined. RESULTS Recent regulatory setbacks, especially involving Asia-centric trials, underscore the consequences of insufficient regional planning. Emerging statistical approaches, including adaptive and Bayesian methods, show promise in managing heterogeneity while preserving trial integrity. Persistent challenges include disparities in trial infrastructure, molecular subtype distributions, and comorbidity patterns. Broader regional inclusion and integration of real-world evidence are increasingly critical to overcoming these limitations. CONCLUSION Regional enrollment should be viewed not as a regulatory formality, but as a scientific and ethical priority. The future of global oncology trials hinges on proactive regional planning, innovative methodology, and cross-sector collaboration. Aligning global efficiency with local relevance can enhance scientific robustness, support regulatory alignment, and expand equitable access to novel cancer therapies worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentNeoplasmsClinical Trials as TopicAntineoplastic AgentsHumansBayes TheoremUnited States

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • European Alliance for Personalised Medicine, Brussels, Belgium.
  • Department of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Faculty of Engineering and Technology, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagra…
  • International Cancer Patient Coalition, Brussels, Belgium.
  • Digestive Cancers Europe, Brussels, Belgium.
  • Tackle Prostate Cancer, London, United Kingdom.
  • Qatar Cancer Society, Doha, Qatar.

ORCID-Profile: Denis Horgan, Zorana Maravic, Hadi Mohamad Abu Rasheed, Carolina Reduzzi, Adda Bounedjar, Roberto Pestana, Jonathan A Lal, Umberto Malapelle, Vivek Subbiah

Zitieren

APA

Horgan, D., Maravic, Z., Mastris, K., Mohamad Abu Rasheed, H., Reduzzi, C., Bounedjar, A., Elghazaly, H., Mohar, A., Pestana, R., Lal, J. A., Malapelle, U., Asgary, R., & Subbiah, V. (2026). Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug Development. JCO Global Oncology. https://doi.org/10.1200/go-25-00285

Vancouver

Horgan D, Maravic Z, Mastris K, Mohamad Abu Rasheed H, Reduzzi C, Bounedjar A, et al. Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug Development. JCO Global Oncology. 2026. doi:10.1200/go-25-00285

BibTeX
@article{Horgan2026,
  author = {Horgan, Denis and Maravic, Zorana and Mastris, Ken and Mohamad Abu Rasheed, Hadi and Reduzzi, Carolina and Bounedjar, Adda and Elghazaly, Hesham and Mohar, Alejandro and Pestana, Roberto and Lal, Jonathan A and Malapelle, Umberto and Asgary, Ramin and Subbiah, Vivek},
  title = {Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug Development},
  journal = {JCO Global Oncology},
  year = {2026},
  doi = {10.1200/go-25-00285}
}
Kostenlos starten →